S.G.). The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/Rationale: Related transcriptional enhancer factor-1 (RTEF-1) plays an important role in endothelial cell function by regulating angiogenesis; however, the mechanism underlying the role of RTEF-1 in the endothelium in vivo is not well defined.
T he endothelium is a complex organ with a multitude of properties essential for controlling vascular functions. Dysfunction of the vascular endothelium plays an important role in the pathogenesis of diabetic microangiopathy and macroangiopathy. Sustained hyperglycemia in metabolic syndrome causes alterations in a large number of transcription factors and mRNA transcripts, which ultimately leads to tissue damage. However, transcription factors involved in glucose homeostasis in response to insulin stimulation in the endothelium have not been fully studied. Previous studies from our laboratory have demonstrated that related transcriptional enhancer factor-1 (RTEF-1, also known as TEF-3 or TEAD4) plays an important role in endothelial cells via regulation of angiogenesis. 1, 2 More recently, studies have indicated that RTEF-1 drives communication between the endothelium and myocardium 3 and enhances endotheliumdependent microvascular relaxation. 4 RTEF-1 is a member of the transcriptional enhancer factor (TEF) family, [5] [6] [7] Editorial, see p 951 a multigene family composed of 4 vertebrate members that share a highly conserved DNA binding domain capable of binding to muscle-CAT (M-CAT) elements found in the promoters of many genes expressed in cardiac and skeletal muscle. 5, 8, 9 In endothelial cells, RTEF-1 is induced by hypoxia as a result of enhanced vascular endothelial growth factor (VEGF) promoter activity. 2 In addition, transgenic mice overexpressing RTEF-1 specifically in the endothelium show a transcriptional regulation of hypoxia-inducible factor-1α, as well as angiogenic ability in the hindlimb ischemia model compared with wild type. 1 Ablation of the mouse RTEF-1 gene causes defects in the production of trophoblast stem cells, trophectoderm, or blastocoel cavities and consequently preimplantation lethality. 10 Insulin-like growth factor binding proteins (IGFBPs) are key regulators of insulin-like growth factor (IGF) type 1 and 2 bioavailability at the cellular level and may exert IGFindependent effects on target cells. The IGFBP superfamily contains 6 high-affinity binding IGFBPs and 9 low-affinity binding IGFBP-related proteins. [11] [12] [13] Growing evidence has shown an association of large-and small-vessel diseases with certain IGFBP-1 abnormalities, which suggests that they may be significant factors in the pathophysiology of cardiovascular disease. 14, 15 Furthermore, acute steady-state hyperinsulinemia decreases serum IGFBP-1 concentration to values that are 40% to 70% lower than baseline in normal individuals and in diabetic patients, which suggests that insulin is involved in the regulation of serum IGFBP-1 levels. 16, 17 Moreover, low levels of IGFBP-1 are associated with metabolic syndrome and cardiovascular diseases in cross-sectional studies 18, 19 and can predict ischemic heart disease mortality. 20 In this report, we examined RTEF-1 involvement in the endothelium-related effect of glucose regulation and its potential transcriptional target in vivo using diet-induced obese transgenic mice and in vitro using cultured endothelial cells to analyze the related mechanism. We demonstrate that RTEF-1 increases IGFBP-1 gene expression by interacting with its insulin response element (IRE). Evidence for a biological role of RTEF-1 in IGFBP-1 regulation includes decreased expression of IGFBP-1 in endothelium-specific RTEF-1 knockout mice (RTEF-1 −/− ) and in endothelial cells deficient in RTEF-1. Conversely, increased IGFBP-1 expression was observed in overexpressing RTEF-1 transgenic mice and in endothelial cells with forced RTEF-1 overexpression. Additionally, RTEF-1 −/− mice exhibited increased blood glucose and insulin sensitivity, which was exacerbated in a high-fat diet (HFD), correlating with decreasing IGFBP-1 levels. Our findings suggest that RTEF-1 is integral in the endothelial regulation of IGFBP-1 and subsequent blood glucose homeostasis.
Methods

Generation of RTEF-1 Transgenic Mice
A conditional knockout line of RTEF-1 was generated by crossing homozygous TEAD4lox/lox mice (a gift from Dr Andres Buonanno, National Institute of Child Health and Human Development, National Institutes of Health) with transgenic mice expressing Cre recombinase under control of the endothelial cell-specific Tie2 promoter/enhancer (a gift from Dr Anthony Rosenzweig, Beth Israel Deaconess Medical Center). 21 RTEF-1 transgenic mice were generated at the Beth Israel Deaconess Medical Center Transgenic Core Facility using the vascular endothelial cadherin (VE-Cad) promoter to drive endothelium-specific expression of human RTEF-1. 22 The investigation conforms to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication No. 85- 23, 1996) and was approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center. For detailed protocols, please refer to the online-only Data Supplement.
Cell Culture and Transfection
Human microvascular endothelial cells (HMEC-1, Centers for Disease Control and Prevention) were cultured in MCDB-131, and human embryonic kidney cells 293 (HEK 293) were cultured in DMEM. Wild-type IGFBP-1 (IGFBP-1FL) or TK.IRS3 or VF-2 mutant promoter luciferase construct, control vector, PXJ40, and/or an increasing amount of RTEF-1 expression vector (generous gifts from Dr Alexandre Stewart, University of Ottawa, Canada) was transfected into HEK 293 cells, as shown in more detail in the online-only Data Supplement.
Retroviral Construction
The RTEF-1 (NM_014059.1) coding sequence was cloned into pBMNgreen fluorescence protein (GFP) vector (Obigen, San Diego, CA) for retrovirus packaging. pBMN-GFP or pBMN-GFP-RTEF-1 was transfected to 293T with polyethylenimine with pVSV-G, pJK3, and pC-MVtat. The medium with retrovirus/RTEF-1 or retrovirus/GFP control was collected and filtered before being used to infect HMEC-1 cells.
siRNA Transfection
Small interfering RNAs (siRNAs) targeting human RTEF-1 were synthesized by Genepharma, Inc (Shanghai, China). Knockdown efficiency of 2 duplexes of RTEF-1 siRNAs or a nontarget control was determined by transfection into HMEC-1 cells at a final concentration of 50 nmol/L according to the manufacturer's protocol. For details on this protocol, please refer to the online-only Data Supplement.
Quantitative Real-Time Polymerase Chain Reaction Analysis
Total RNA was extracted from the apex of mouse hearts from wild-type (WT) and transgenic mice, as well as the RTEF-1-overexpressing and GFP stably expressing HMEC-1 cell lines. A total of 2.0 μg of RNA from both endothelial cell lines stably transfected with RTEF-1 or isolated from the apex of WT, RTEF-1-overexpressing, and RTEF-1 endothelial cell-specific knockout transgenic mouse hearts was reverse-transcribed. Quantitative real-time polymerase chain reaction amplification was performed with SYBR Green Master Mix (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol, as outlined in detail in the online-only Data Supplement.
ELISA and Blood Glucose Analysis
Blood glucose levels were obtained from feed-deprived (overnight), restrained, unanesthetized mice. Blood was obtained via submandibular bleed, and plasma IGFBP-I concentration was measured by ELISA. Insulin resistance (IR) was assessed from fasting insulin and glucose levels by the previously validated homeostasis model assessment (HOMA-IR). 23 Please refer to the online-only Data Supplement for details.
Metabolic Studies
Glucose tolerance tests and insulin tolerance tests were performed in 5-month-old conscious WT and transgenic mice. For glucose tolerance tests, glucose was injected intraperitoneally. Blood glucose was measured by tail bleeding at serial time points after glucose injection. For insulin tolerance tests, mice were injected with insulin and blood glucose was measured at the same time points as for glucose tolerance tests, as shown in detail in the online-only Data Supplement.
Non-standard Abbreviations and Acronyms IGF
insulin-like growth factor IGFBP insulin-like growth factor binding protein RTEF-1 related transcriptional enhancer factor-1 TEF transcriptional enhancer factor VE-Cad vascular endothelial cadherin
Promoter Activity and Chromatin Immunoprecipitation
HEK293 cells were transfected with constructs with or without RTEF-1, indicated in the Figure legends. Luciferase activity was determined using the dual luciferase assay system (Promega, Madison, WI).
Chromatin immunoprecipitation was performed with the ChIP-IT Express Kit (Active Motif, Carlsbad, CA) in accordance with the manufacturer's instructions, with primers shown in detail in the online-only Data Supplement.
Immunoblot Analysis
RTEF-1 and GFP stably transfected HMEC-1 cells were lysed and protein concentrations determined. Samples were subjected to SDS-PAGE, transferred to nitrocellulose membranes (Whatman, Springfield Mill, United Kingdom), and subsequently blocked in TBS-Tween 20 containing 5% nonfat milk for 1 hour. The membranes were incubated with the indicated primary antibodies: Polyclonal anti-IGFBP-1 antibody; polyclonal anti-RTEF-1 antibody, monoclonal anti-vinculin followed by incubation with horseradish peroxidaseconjugated secondary antibodies anti-rabbit or anti-mouse IgG. Blots were developed with the chemiluminescence detection system according to the instructions of the manufacturer (Thermo Fisher Scientific, Rockford, IL). Densitometric analysis was performed with the National Institutes of Health software program Image J. The online-only Data Supplement provides more details.
Immunofluorescence
Hearts were removed from transgenic and littermate control mice, embedded in OCT compound, and frozen at −80°C. Tissues were sectioned, fixed in 4% paraformaldehyde, and stained with antibodies against RTEF, followed by incubation with goat anti-rabbit FITC and goat anti-mouse TRITC secondary antibodies (Santa Cruz, Santa Cruz, CA). Immunofluorescence stained sections were visualized with a DM5000B upright microscope, as shown in the online-only Data Supplement.
Blood Pressure Measurements
Blood pressure was measured noninvasively on conscious mice with a volume-pressure recording tail-cuff system (CODA system by Kent Scientific Corp, Torrington, CT). Additionally, blood pressure was confirmed by telemetry, as described in detail in the online-only Data Supplement.
Nuclear Magnetic Resonance Determination of Body Composition
Body composition was measured in both WT and RTEF-1 −/− mice on both a normal chow diet (NCD) and a high fat diet (HFD) with quantitative nuclear magnetic resonance. Live, conscious, unrestrained mice were placed in small tubes and inserted into a Brucker model mq10 NMR analyzer (Brucker, Canada; Milton, Ontario, Canada). Total fat, lean, and water mass were recorded after <1 minute. Measurements were performed in triplicate.
Statistical Analysis
Data were obtained from at least 3 independent cell cultures or animals, as denoted in the Figure legends. Data are presented as mean±SEM.
The trapezoidal rule was used to determine the area under the curve. HOMA-IR was calculated as (fasting glucose level×fasting insulin level)/22.4. The level of statistical significance was determined with Student 2-tailed t test when differences between the means of 2 populations were considered. Comparison of multiple time points between groups was made with a 1-way or 2-way repeated-measures ANOVA.
Results
IGFBP-1 Expression Is Attenuated in RTEF-1-Deficient Transgenic Mice
RTEF-1 is one of the earliest transcription factors expressed during mammalian development, and elimination of RTEF-1 expression in mice causes cardiac defects that result in embryonic lethality. 10, 24 To examine the importance of the RTEF-1 gene in endothelium, we generated a conditional endothelial cell-specific RTEF-1 knockout mouse (RTEF-1 −/− ). To conditionally delete the functional mouse RTEF-1 locus, 2 loxP sites were inserted into the introns flanking its second exon ( Figure 1A ).
The targeting vector contained a pGK-neo cassette for positive selection and a pGK-tk cassette for negative selection against nonhomologous recombinants. 10 Homozygous mice were bred as described previously 10 and mated with Tie2-Cre mice that expressed Cre recombinase specifically in endothelial cells. 21 RTEF-1 −/− mice were genotyped by reverse transcription-polymerase chain reaction ( Figure 1B ). There were no gross morphological or developmental changes in the RTEF-1 −/− transgenic mice and no evidence indicating that strong expression of Cre recombinase induced abnormalities in WT littermate mice. Additionally, to rule out the potential loss of RTEF-1 in hematopoietic cells using a Tie2-Cre promoter, bone marrow from WT and RTEF-1 −/− mice were analyzed for RTEF-1 levels (Online Figure I) . No significant differences were found. Originally, DNA microarray data from RTEF-1overexpressing endothelial cells illustrated that a handful of insulin-regulated genes had significant changes, including IGFBP family members (data not shown), which was verified by quantitative polymerase chain reaction ( Figure 1C ) immunoblot ( Figure 1D ). IGFBP-1 levels were decreased significantly in the apex of the RTEF-1 −/− hearts compared with littermate controls. We further confirmed that the absence of RTEF-1 was localized in the endothelium by double immunostaining with antibodies to endothelial marker CD31 and RTEF-1 in hearts from RTEF-1 −/− and littermate controls ( Figure 1E ).
Effect of RTEF-1 Ablation on Diet-Induced Obesity
We next examined the metabolic effect of RTEF-1 deletion on mice fed a NCD versus a HFD. Five-week-old male RTEF-1 −/− and WT mice were fed either NCD or HFD (42% kcal from fat) for 15 weeks. The HFD is a well-established model for obesity-induced insulin resistance. 25 Although the HFD increased growth rate and final body weight compared with mice fed the NCD, RTEF-1 did not significantly alter body weight with either diet (Table) , nor did it change the percentage of skeletal muscle or adipose tissue in WT and RTEF-1 −/− mice (Online Figure IIA and IIB). Obesity is typically associated with decreased insulin sensitivity and elevated circulating concentrations of glucose and insulin. Initially, blood glucose levels were screened in RTEF-1 −/− mice and WT mice, and as shown in Figure 2A , fasting blood glucose levels were modestly increased in RTEF-1 −/− compared with WT mice on the NCD. Despite having a similar body weight and fat-pad mass, overnight fasting blood glucose ( Figure  2A ) and 6-hour fasting plasma insulin concentrations ( Figure  2B ) were increased in obese RTEF-1 −/− mice compared with littermate controls fed a HFD, which suggests an impaired insulin sensitivity. Serum insulin levels were increased ≈2-fold ( Figure 2B ) in RTEF-1 −/− versus littermate controls fed either September 28, 2012 a NCD or HFD. Furthermore, obese RTEF-1 −/− mice demonstrated a decrease in IGFBP-1 levels by ≈4-fold compared with their littermate controls ( Figure 2C ). Additionally, serum IGFBP-1 levels were decreased in the WT HFD cohort compared with the previous WT NCD ( Figure 2C ), which suggests that obesity decreases serum IGFBP-1 levels.
Insulin Resistance in Obese RTEF-1 −/− Mice
We evaluated insulin sensitivity and glucose homeostasis in RTEF-1 −/− and littermate controls fed either a NCD or HFD. As shown in Figure 3A and 3B, the ability to regulate blood glucose levels in response to an intraperitoneal glucose tolerance test (1 g/kg body weight) or an intraperitoneal insulin tolerance test (0.75 U/kg) challenge was not significantly impaired in transgenic mice versus WT mice maintained on the NCD. In contrast, glucose tolerance was significantly impaired in obese RTEF-1 −/− mice compared with the littermate controls ( Figure 3C ). After intraperitoneal administration of insulin (0.75 U/kg), glucose excursion from blood was increased slightly in RTEF-1 −/− mice compared with WT mice maintained on the HFD ( Figure  3D ). However, RTEF-1 −/− mice fed a HFD were significantly insulin resistant compared with littermate control mice. Additionally, the area under the curve (AUC) was calculated and was significantly different in the transgenic RTEF-1 −/− mice fed a HFD, which further indicates their insulin resistance (Online Figure IIIA and IIIB). Insulin resistance was also assessed via HOMA-IR and was increased significantly in both the NCD-fed and obese RTEF-1 −/− mice compared with littermate controls, which indicates that the ability of circulating insulin to regulate fasting blood glucose levels was impaired (Online Figure IIIA and IIIB).
Effect of RTEF-1 Ablation on Cardiac Function
To assess the effect of endothelium-specific removal of RTEF-1 and obesity on the heart, cardiac parameters of RTEF-1 −/− mice were assessed (Table) . No significant difference in heart rate or systolic blood pressure was detected between the groups. Additionally, telemetry was performed to confirm the blood pressure measurements taken in the RTEF-1 −/− and control mice by a volume-pressure recording tail-cuff system (Online Figure IV ). Although no difference in blood pressure was detected, echocardiography revealed a significant decline of heart function in both control and RTEF-1 −/− mice fed a HFD (Table 1; 45.8±2.9% versus 37.5±6%).
RTEF-1 Induced IGFBP-1 Expression in Endothelial Cells
To confirm that IGFBP-1 might be a potential target gene of RTEF-1 and investigate the mechanism involved, RTEF-1 was overexpressed in HMEC-1 by retroviral infection. RTEF-1 and IGFBP mRNA were examined by quantitative real-time polymerase chain reaction ( Figure 4A ). IGFBP-1 mRNA expression and secreted IGFBP-1 ( Figure 4B ) were increased markedly in RTEF-1-overexpressing cells compared with control cells. To verify that RTEF-1 was necessary to increase IGFBP-1 levels, siRNAs were used to knockdown RTEF-1 expression. RTEF-1 levels were decreased significantly in human umbilical vein endothelial cells, which resulted in an almost 70% reduction in IGFBP-1 levels ( Figure 4C ). When HMEC-1 cells were treated with insulin, IGFBP-1 mRNA levels decreased ( Figure 4D ). Increasing insulin concentrations also dose-dependently decreased RTEF-1 mRNA levels ( Figure 4E ). Furthermore, when cells were treated with RTEF-1 siRNA, insulin was unable to significantly regulate IGFBP-1 levels compared with control ( Figure 4F ).
IGFBP-1 Is a Potential Target Gene of RTEF-1
To determine whether IGFBP-1 was regulated by RTEF-1 on a transcriptional level via the IGFBP-1 promoter, we performed luciferase reporter assays. The IGFBP-1 promoter exhibited an RTEF-1 dose-dependent increase in activity, exhibiting a maximum of a 3.7±0.4-fold increase ( Figure  5B ). Many of the important cis-regulatory elements are located within 500 bp of the transcription start site in the IGFBP-1 promoter ( Figure 5A ). The hepatocyte nuclear factor 1 (HNF1) binding region, cAMP response element (CRE), IRE, glucocorticoid response element (GRE), and TATA element are highly conserved among the human, rat, baboon, and mouse IGFBP-1 promoters. 26 Previously, it has been shown that RTEF-1 regulates its target genes through the muscle-CAT element and can also transcriptionally regulate vascular endothelial growth factor through its Sp1 site. 2 Analysis of the IGFBP-1 promoter revealed that there were no typical muscle-CAT sites or Sp1 sites on the IGFBP-1 promoter, so we examined whether this effect of RTEF-1 was mediated through its IRE ( Figure 5A ). Additionally, IGFBP-1 has been reported to be regulated by other transcription factors, such as FOXO1, through its IRE. 27, 28 The IGFBP-1 promoter contains an IRE that includes 2 insulin response sites (IRSs) located ≈100 bp 5′ to the RNA cap site, IRSA (CAAAACAA) and IRSB (TTATTTTG), and each is sufficient to mediate the negative effects of insulin on promoter activity. To determine whether RTEF-1 possibly regulates IGFBP-1 via its IRS, an array of IRSs (TK.IRS3) were introduced immediately upstream from the thymidine kinase promoter. 27 The TK.IRS3 was sufficient to confer effects of RTEF-1 on promoter activity ( Figure 5C and 5D) , as evidenced by the 4.9±0.03-fold increase in the TK.IRS3 luciferase reporter construct. This was confirmed by the inability of RTEF-1 to increase promoter activity in the IGFBP-1 Figure 2 . RTEF-1 −/− (related transcriptional enhancer factor-1-deficient) transgenic mice have lower insulin-like growth factor binding protein (IGFBP-1) levels and increased insulin resistance according to the homeostasis model assessment. A, Blood glucose levels were obtained from food-deprived (overnight), restrained, unanesthetized mice. Blood was obtained via submandibular bleed, and glucose was quantified with a CVS Truetrack glucose monitor at 8 weeks of age on wild-type (WT) and RTEF-1 −/− mice fed a normal chow (NCD) or high-fat diet (HFD). Blood glucose was significantly higher in the transgenic mice that lacked RTEF-1 in the endothelium in both the NCD and HFD (*P=0.022; n=18 mice). B, Serum insulin concentration was measured by ELISA with a maximum absorbance of 450 nm. The limit of sensitivity is ≥0.121 ng/mL. C, Serum IGFBP-I concentration was measured by ELISA. IGFBP-1 concentration was measured with a maximum absorbance of 450 nm. The limit of sensitivity is ≥31.2 pg/mL. n=3; *P=0.035. IGFBP-1 levels correlated inversely with blood glucose levels in these mice. Figure 3 . Obese RTEF-1 −/− (related transcriptional enhancer factor-1deficient) transgenic mice have decreased glucose tolerance and increased insulin resistance. A, Glucose tolerance in wild-type (WT) and RTEF-1 −/− mice. Glucose was measured before and 30, 60, and 120 minutes after intraperitoneal glucose injection at 15 weeks of age. B, Insulin tolerance in WT and RTEF-1 −/− was analyzed; glucose was measured before and 30, 60, and 120 minutes after intraperitoneal insulin injection. Data are presented as mean±SD (n=7-9 animals per group). *P≤0.05 and **P≤0.01 for RTEF-1 −/− vs WT. C, Glucose tolerance in WT and RTEF-1 −/− mice was measured before and 30, 60, and 120 minutes after intraperitoneal glucose injection. D, Insulin tolerance in WT and RTEF-1 −/− mice at 15 weeks of HFD; glucose was measured before and 30, 60, and 120 minutes after intraperitoneal insulin injection. Data are presented as mean±SD (n=7-9 animals per group). *P≤0.05 and **P≤0.01 for RTEF-1 −/− vs WT.
VF2 mutant, which lacked the IRE sequence ( Figure 5B and 5E). Additionally, as shown in Figure 5D , the IRE mutation disrupted the ability of RTEF-1 to stimulate IGFBP-1 promoter activity in a dose-dependent manner, whereas the IRS sequence was sufficient to confer effects of RTEF-1 on IGFBP-1 promoter activity, as shown in Figure 5C . To further investigate the IRE as the key element in RTEF-1 regulation of IGFBP-1 transcription, a chromatin immunoprecipitation assay was performed ( Figure 5F ). Primers were designed to flank the IRE sequence of IGFBP-1, and the chromatin immunoprecipitation assay demonstrated that RTEF-1 specifically bound to the IGFBP-1 IRE promoter region. Taken together, these results imply that RTEF-1, much like the forkhead transcription factors, exerts effects on IGFBP-1 promoter activity through its IRE.
Overexpression of RTEF-1 in the Endothelium Improved Glucose Tolerance in Obese Mice
Some of the physiological consequences of diet-induced obesity are insulin resistance, glucose intolerance, and the eventual development of overt diabetes. We evaluated whether mice overexpressing RTEF-1 showed any changes in glucose tolerance after prolonged exposure to a HFD. Interestingly, Figure  6A demonstrates that blood glucose levels were increased in WT mice fed a HFD compared with the VE-Cad/RTEF-1 mice. In correlation with the previous data in the RTEF-1 −/− mice, serum IGFBP-1 levels in both WT and VE-Cad/RTEF-1 mice were decreased in response to the HFD; however, VE-Cad/RTEF-1 mice had significantly higher levels than WT ( Figure 6B ).
To determine whether IGFBP-1 levels were affected in VE-Cad/RTEF-1 mice, we analyzed IGFBP-1 levels in these mice. Figure 6C demonstrates that VE-Cad/RTEF-1 mice had significantly higher IGFBP-1 serum levels than littermate controls, despite the decrease that resulted from the HFD. In addition, both the AUC and HOMA-IR were significantly increased in WT mice compared with VE-Cad/RTEF-1 transgenic mice, which indicates that the ability of circulating insulin to regulate fasting blood glucose levels was not significantly impaired in VE-Cad/RTEF-1 mice (Online Figure  IIIC) . When intraperitoneal glucose tolerance test experiments were performed after 24 weeks of a HFD, VE-Cad/RTEF-1 mice displayed a markedly improved glucose tolerance and insulin sensitivity compared with the WT mice fed a similar HFD, which suggests protection from the HFD-induced insulin resistance.
Discussion
The present studies revealed an important role of RTEF-1 in the regulation of IGFBP-1 and potential glucose homeostasis. First, we demonstrated that IGFBP-1 is a target gene of RTEF-1 and that RTEF-1 can increase IGFBP-1 levels in the endothelium both in vitro and in vivo. Second, we identified an IRE element in the IGFBP-1 promoter to which RTEF-1 binds directly. Third, ablation of RTEF-1 from the endothelium significantly decreased circulating IGFBP-1 serum levels, Figure 5 . RTEF-1 (related transcriptional enhancer factor-1) upregulates transcription of insulin-like growth factor binding protein (IGFBP-1) through its insulin response element site. A, IGFBP-1 full-length (FL) promoter sequences designating binding elements. B, Schematic of IGFBP-1 promoter. IGFBP-1 FL promoter was transiently cotransfected with increasing concentrations of RTEF-1, and luciferase activity was examined. C, Transient transfections using a set of IGFBP-1 promoter luciferase constructs (300 ng) and control vector (600 ng; black bar) or equal amount of RTEF-1 cDNA (gray bar). D, The truncated IRS-3 repeat promoter was transiently cotransfected with increasing concentrations of RTEF-1, and luciferase activity was examined. E, The mutant VF-2 promoter was transiently cotransfected with increasing concentrations of RTEF-1, and luciferase activity was examined. F, Chromatin immunoprecipitation assays were performed by immunoprecipitating chromatin from human microvascular endothelial cells (HMEC-1) with control IgG or an anti-RTEF-1 antibody and performing reverse transcription-polymerase chain reaction with primers to the insulin response element site on the IGFBP-1 promoter or another control to the actin promoter. The results are from 3 independent experiments (mean±SD). *P≤0.05; P≤0.01 increased glucose intolerance and insulin resistance, and decreased fractional shortening. Finally, IGFBP-1 expression regulated by RTEF-1 overexpression resulted in improved glucose tolerance and insulin sensitivity.
As a member of the transcriptional enhancer factor family, RTEF-1 binds to the muscle-CAT regulatory element in promoters of muscular genes to direct gene expression. 5 However, the abilities of RTEF-1 in nonmuscle cells have not been fully investigated. We have previously reported that RTEF-1 is involved in hypoxia-induced angiogenesis through its target genes, including hypoxia-inducible factor-1α 1 and vascular endothelial growth factor 3 in endothelial cells, and that RTEF-1 increases endothelium-specific coronary microvascular 2 relaxation, 4 which indicates an importance in further understanding the role of RTEF-1 in endothelium. Endothelium-specific RTEF-1-deficient transgenic mice provide an efficient model to dissect the function of RTEF-1 in endothelium. Interestingly, RTEF-1 −/− transgenic mice fed a NCD were normoglycemic in the fasting state, appeared to be glucocompetent when assessed by an intraperitoneal glucose tolerance test, and showed only slightly impaired insulin sensitivity. In contrast, when these mice were fed a HFD, both the transgenic mice and littermate controls demonstrated impaired glucose tolerance, hyperinsulinemia, and impaired insulin sensitivity. However, the RTEF-1 −/− mice showed significantly increased hyperglycemia, impaired glucoregulation, and increased HOMA-IR scores, the main features of insulin-resistant states. These findings revealed a novel ability of RTEF-1, as a transcription factor, to be involved in glucose regulation via IGFBP-1.
The present study indicates that IGFBP-1 is a potential target gene of RTEF-1 and plays a key role in RTEF-1 regulation of glucose homeostasis. Previous reports indicated that lower concentrations of IGFBP-1 were found in patients with diabetes and macrovascular disease. 29, 30 The present findings substantiate the conclusion that IGFBP-1 is negatively associated with insulin resistance. [31] [32] [33] [34] [35] This indicates IGFBP-1 may simply be a marker of metabolic improvements and reduced insulinemia, yet more current research suggests that IGFBP-1 exerts direct metabolic effects. For example, IGFBP-1 binds integrin receptors, which leads to cross talk between integrin receptors and insulin signaling pathways that may lead to increased insulin sensitivity. 36, 37 In human longitudinal studies, IGFBP-1 concentrations were lower in obese children with metabolic syndrome than in obese children without. 35 Additionally, mean IGFBP-1 levels were significantly lower in human subjects with abdominal obesity (P<0.001), elevated fasting glucose (P<0.001), hypertension (P<0.001), low highdensity lipoprotein cholesterol (P<0.001), and metabolic syndrome (P<0.001) than in control subjects without these metabolic abnormalities. 32 In rodent models, overexpression of IGFBP-1 resulted in dysregulation of the insulin/IGFBP axis and is a model of reduced sensitivity of IGFBP-1 to insulin regulation. 38, 39 However, more recent studies in mice that backcrossed human-IGFBP-1 to a C57BL/6 background demonstrated that IGFBP-1 had a protective effect on susceptibility to glucose intolerance and insulin resistance when the mice were challenged with nutritional obesity, which correlates with other recent data pooled from rodent studies on IGFBP-1 in glucose regulation. 40 To clarify more precise information regarding the role of RTEF-1 in the regulation of IGFBP-1 and its physiological Figure 6 . Obese vascular endothelial cadherin/related transcriptional enhancer factor-1 (VE-Cad/RTEF-1)-overexpressing mice show restored glucose tolerance and circulating insulin-like growth factor binding protein (IGFBP-1). A, Blood glucose levels were obtained from food-deprived (overnight), restrained, unanesthetized mice. Blood was obtained via submandibular bleed, and glucose was quantified with a CVS Truetrack glucose monitor on wild-type (WT) and VE-Cad/ RTEF-1 mice fed a high-fat diet. Blood glucose was significantly lower in the transgenic mice that overexpressed RTEF-1 in the endothelium (*P≤0.05; n=18 mice). B, Serum IGFBP-I concentration was measured by ELISA. IGFBP-1 concentration was measured with a maximum absorbance of 450 nm. The limit of sensitivity is ≥31.2 pg/ mL. (n=3; *P≤0.05). IGFBP-1 levels inversely correlated with blood glucose levels in these mice. C, Serum insulin concentration was measured by ELISA with a maximum absorbance of 450 nm. The limit of sensitivity is ≥0.121 ng/mL. D, Glucose tolerance in WT and VE-Cad/RTEF-1 mice; glucose was measured before and 30, 60, and 120 minutes after intraperitoneal glucose injection. E, Insulin tolerance in WT and VE-Cad/RTEF-1 mice at 15 weeks of high-fat diet; glucose was measured before and at, 30, 60, and 120 minutes after intraperitoneal insulin injection. Data are presented as mean±SD (n=7-9 animals per group). *P≤0.05 and **P≤0.01 for VE-Cad/RTEF-1 vs WT.
